Haima Therapeutics
PrivateLast Round
Grant
Sep 19, 2025
Total Funding Raised
$6.63M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Haima Therapeutics is a biotechnology company that develops cell-inspired therapies to mitigate bleeding and other blood-related disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Advanced Materials, Defense Tech, Clinical Trials
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Haima Therapeutics Comparables
Compare Haima Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SelSym Biotech | 92% | |
| Cayuga Biotech | 86% | |
| Cellphire Therapeutics | 83% | |
Haima Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 19, 2025 | ||||
| Grant | Jun 24, 2020 | ||||
| Grant | Feb 1, 2020 | ||||
| Grant | Oct 19, 2018 | ||||
| Grant | May 15, 2018 |
Key People
Founding team and executive leadership
Haima Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Ohio Third Frontier | Grant |
| U.S. Department of War | Grant |
| National Heart, Lung, and Blood Institute | Grant |
| Defense Advanced Research Projects Agency | Grant |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 2, 2026
Monthly visitors grew 4016% MoM, reaching 8.7K.
- Sep 19, 2025
$4M grant from Defense Advanced Research Projects Agency
Haima Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |